NCT04744207 - A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions

Systemic Sclerosis

Interventions

DRUG

GS-248

120 mg, capsule, once daily for 4 weeks

DRUG

Placebo

capsule, once daily for 4 weeks

Trial Locations (12)

Investigator site, Ghent

Investigator Site, Nijmegen

Investigator site, Gdansk

Investigator Site, Krakow

Investigator site, Lublin

Investigator site, Bath

Investigator site, Cambridge

Investigator Site, Dundee

Investigator site, Leeds

Investigator Site, Liverpool

Investigator Site, London

Investigator site, Manchester